Apixaban for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the baseline risk of major bleeding, we used data from 2 randomized trials on people with VTE, showing that the risk of major bleeding with placebo during 18 or 24 months of follow-up was as low as 0.5% 306 and as high as 1.5% in 18 months. 259”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Self-citation
Research works printed but not linked: 1
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Items 201–300 of 1,000
Multimodal assessment of non‐specific hemostatic agents for apixaban reversal
Martin, A., Gouin‐Thibault, I., Siguret, V., Mordohay, A., Samama, C. M., Gaussem, P., Bonniec, B. L., & Godiér, A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12830 · Cited by 51
Pharmacology and mechanisms of action of new oral anticoagulants
Salem, J., Sabouret, P. F., Funck‐Brentano, C., & Hulot, J. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12091 · Cited by 56
Kempny, A., McCabe, C., Dimopoulos, K., Price, L., Wilde, M., Limbrey, R., Gatzoulis, M. Α., & Wort, S. J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.10.001 · Cited by 47
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
Thaler, J., Pabinger, I., & Ay, C. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00030 · Cited by 58
“Both treatment doses of apixaban similarly reduced the risk of recurrent VTE without an increased risk of major bleeding (29).”
BackgroundPeri-procedural management of patients taking oral anticoagulants
Daniels, P. R. (2015) · BMJ · doi:10.1136/bmj.h2391 · Cited by 47
Larsen, T., Garresori, H., Brekke, J., Enden, T. R., Frøen, H., Jacobsen, E. M., Quist‐Paulsen, P., Porojnicu, A. C., Ree, A. H., Torfoss, D., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15666 · Cited by 45
Radadiya, D. K., Devani, K., Brahmbhatt, B. S., & Reddy, C. M. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002035 · Cited by 55
Houghton, D. E., Vlazny, D. T., Casanegra, A. I., Brunton, N. E., Froehling, D. A., Meverden, R. A., Hodge, D. O., Peterson, L. G., McBane, R. D., & Wysokiński, W. E. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.026 · Cited by 46
“in the treatment and secondary prevention of venous thromboembolism (VTE) (1-6) but since patients with cancer-associated VTE (Ca-VTE) are at increased risk for both recurrent VTE and bleeding new studies specifically designated for Ca-VTE were necessary.”
BackgroundArrington‐Sanders, R., Connell, N. T., Coon, D., Dowshen, N., Goldman, A. L., Goldstein, Z. G., Grimstad, F. W., Javier, N. M., Kim, E., Murphy, M. C., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.008 · Cited by 46
Vlieg, M. A. M. V. H., Nasserinejad, K., Visser, C., Bramer, W. M., Ashrani, A. A., Bosson, J., Crusan, D. J., D’Alessio, A., Fluharty, M., Ģībietis, V., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102194 · Cited by 52
Song, Y., Chang, M., Suzuki, A., Frost, R. J. A., Kelly, A., LaCreta, F., & Frost, C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.05.004 · Cited by 43
Sindet-Pedersen, C., Pallisgaard, J. L., Staerk, L., Berger, J. S., Lamberts, M., Torp-Pedersen, C., Gislason, G. H., & Olesen, J. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-03596-x · Cited by 44
Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?
Carroll, B., & Piazza, G. (2018) · Vascular Medicine · doi:10.1177/1358863x18755927 · Cited by 53
Sex matters: Practice 5P's when treating young women with venous thromboembolism
Bistervels, I. M., Scheres, L. J. J., Hamulyák, E. N., & Middeldorp, S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14549 · Cited by 48
Apixaban and rivaroxaban in patients with acute venous thromboembolism
Bott-Kitslaar, D. M., McBane, R. D., Casanegra, A. I., Houghton, D. E., Froehling, D. A., Vlazny, D. T., Ashrani, A. A., Hodge, D. O., Vargas, E. R., Bartlett, M. A., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.09.022 · Cited by 43
Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants
Ageno, W., Caramelli, B., Donadini, M. P., Girardi, L., & Riva, N. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00281-3 · Cited by 56
Ageno, W., & Beyer‐Westendorf, J. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0484 · Cited by 46
“Subgroup analyses showed that both doses of apixaban were effective and well-tolerated, regardless of age, sex, body weight, renal impairment, or whether the index event was DVT or PE (68).”
BackgroundMethodInfluentialCurrent challenges and future prospects in oral anticoagulant therapy
Czuprynska, J., Patel, J. P., & Arya, R. (2017) · British Journal of Haematology · doi:10.1111/bjh.14714 · Cited by 45
Sobieraj, D. M., Coleman, C. I., Pasupuleti, V., Deshpande, A., Kaw, R., & Hernandez, A. V. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.032 · Cited by 42
Transgender patients and the role of the coagulation clinician
Connors, J. M., & Middeldorp, S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14626 · Cited by 42
Managing pulmonary embolism from presentation to extended treatment
Cohen, A. T., Dobromirski, M., & Gurwith, M. M. P. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.09.040 · Cited by 49
“In the AMPLIFY-EXT study of apixaban (2.5 or 5 mg bid) versus placebo given for 12 months in patients who had completed 6–12 months of anticoagulation treatment, there was a significant reduction in recurrent VTE or VTE-related death with apixaban compared with placebo (1.7% for both apixaban doses vs. 8.8%; P b 0.001…”
BackgroundMethodInfluentialSelf-citationWu, C. M., Alotaibi, G., AlSaleh, K. A., Linkins, L., & McMurtry, M. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.033 · Cited by 43
“Three of the studies compared a DOAC (dabigatran, apixaban, and rivaroxaban) to placebo [12,28, 29], and one study, the RE-MEDY trial, used an active comparator (dabigatran vs.”
BackgroundResultBertoletti, L., Ollier, É., Duvillard, C., Delavenne, X., Beyens, M., Magalhaes, É. D., Bellet, F., Basset, T., Mismetti, P., & Laporte, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.023 · Cited by 47
Caliskan, M., TÜKEL, H. C., Benlidayı, E., & Deniz, A. (2017) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.21942 · Cited by 42
“The majority of DOACs including rivaroxaban(5) and apixaban (6) inhibit FXa.”
BackgroundA Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Joppa, S., Salciccioli, J. D., Adamski, J., Patel, S. I., Wysokiński, W. E., McBane, R. D., Al‐Saffar, F., Esser, H., & Shamoun, F. E. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020029 · Cited by 49
“In regard to treatment for VTE, apixaban was shown to be non-inferior to enoxaparin [106,107].”
BackgroundSemmler, G., Lindorfer, A., Schaefer, B., Bartl, S., Hametner‐Schreil, S., Gensluckner, S., Balcar, L., Pomej, K., Lampichler, K., Trauner, M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.024 · Cited by 42
Meta-analysis on risk of bleeding with apixaban in patients with renal impairment
Pathak, R., Pandit, A., Karmacharya, P., Aryal, M. R., Ghimire, S., Poudel, D. R., & Shamoun, F. E. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.10.042 · Cited by 41
Couturaud, F., Pernod, G., Presles, É., Duhamel, E., Jégo, P., Provost, K., Pan‐Petesch, B., Sollier, C. B. D., Tromeur, C., Hoffmann, C., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.210971 · Cited by 47
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease: Lessons From the COMPASS Trial
Coppens, M., Weitz, J. I., & Eikelboom, J. W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313141 · Cited by 45
Self-citationHerndon, K., Guidry, T. J., Wassell, K., & Elliott, W. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019897053 · Cited by 41
“Dosing appropriateness was evaluated in the apixaban group based on the package insert and the AMPLIFY-EXT trial.(7,20) The 2 study groups were not matched at baseline, and no preset power was determined prior to the study.”
MethodEffective diagnosis and treatment of pulmonary embolism: Improving patient outcomes
Meyer, G. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.05.006 · Cited by 48
How I treat recurrent deep-vein thrombosis
Kyrle, P. A. (2015) · Blood · doi:10.1182/blood-2015-09-671297 · Cited by 42
Fang, M. C., Reynolds, K., Fan, D., Prasad, P. A., Sung, S. H., Portugal, C., Garcia, E. A., & Go, A. S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28033 · Cited by 49
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Upreti, V., Song, Wang, Byon, Boyd, Pursley, LaCreta, & Frost (2013) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s41999 · Cited by 40
“Apixaban is also being developed for the treatment of deep vein thrombosis and/or pulmonary embolism.(9,10) Dovepress”
BackgroundGerotziafas, G., Mahé, I., & Elalamy, I. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s49063 · Cited by 47
“5 and 5 mg, twice-daily) with placebo in 2,482 patients with VTE who had completed 6–12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy.(33) The study drugs were administered for 12 months.”
MethodNew anticoagulants for the treatment of venous thromboembolism
Fernandes, C. J. C. D. S., Alves, J. L., Gavilanes, F., Prada, L. F., Morinaga, L. T. K., & Souza, R. (2016) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562016042020068 · Cited by 70
“Apixaban Factor Xa inhibitor Agnelli et al.(23,24) Apixaban 10 mg every 12 h for 7 days; 5 mg every 12 h 6 Apixaban (2.3”
BackgroundInfluentialGuo, W., Chen, X., Tian, X., & Li, L. (2019) · Clinical Epidemiology · doi:10.2147/clep.s219335 · Cited by 41
“(AMPLIFY-EXT) trial showed that the risk of GI bleeding was significantly lower after oral apixaban than after warfarin.(25) Since there is currently no head-to-head RCT that compares all NOAC regimens, there is no definite con-”
BackgroundUse of direct oral anticoagulants in daily practice.
Almarshad, F., Alaklabi, A. A., Bakhsh, E., Pathan, A. R., & Almegren, M. (2018) · Europe PMC (PubMed Central) · Cited by 50
Song, Y. J., Wang, X., Perlstein, I., Wang, J. J., Badawy, S. I. F., Frost, C. E., & LaCreta, F. P. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.497 · Cited by 41
Kumano, O., Akatsuchi, K., & Amiral, J. (2021) · Biomedicines · doi:10.3390/biomedicines9030264 · Cited by 45
Anticoagulant use in older persons at risk for falls: therapeutic dilemmas—a clinical review
Mitchell, A., Elmasry, Y. E. T., van Poelgeest, E. P., & Welsh, T. J. (2023) · European Geriatric Medicine · doi:10.1007/s41999-023-00811-z · Cited by 44
“1 3 for extended VTE treatment and anticoagulant dosing has largely been derived from randomised controlled trials which under-represented older people, only 15% of those included in the apixaban trial were aged ≥ 75 years [79], and the average ages of participants in the rivaroxaban and dabigatran trials were 58 and…”
MethodBetrixaban (PRT054021): pharmacology, Dose Selection and Clinical Studies
Chan, N., Hirsh, J., Ginsberg, J. S., & Eikelboom, J. W. (2013) · Future Cardiology · doi:10.2217/fca.13.98 · Cited by 40
Zhang, L., Kong, D., Wang, H., Jiao, L.-T., Zhao, X., Song, J., Yang, D., Yang, H., Yang, S., Du, G., et al. (2021) · Molecules · doi:10.3390/molecules26092677 · Cited by 39
Alhousani, M. M., Malik, S. U., Abu-Hashyeh, A., Poznanski, N. J., Al-Hasan, S., Roth, D. F., Alsharedi, M. F., & Mustafa, B. O. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.11.036 · Cited by 40
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.
Wang, K.-L., Chu, P. H., Lee, C., Pai, P. Y., Lin, P.-Y., Shyu, K. G., Chang, W., Chiu, K., Huang, C.-L., Lee, C. Y., et al. (2016) · Europe PMC (PubMed Central) · doi:10.6515/acs20151228a · Cited by 49
Reiffel, J. A., Weitz, J. I., Reilly, P. A., Kaminskas, E., Sarich, T. C., Sager, P. T., & Seltzer, J. H. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.04.010 · Cited by 38
Self-citationGómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A., & Vargas, E. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50543 · Cited by 43
Liu, X., Johnson, M. R., Mardekian, J., Phatak, H. M., Thompson, J. R., & Cohen, A. T. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002340 · Cited by 45
“5%).(13) VTE recurrence accounted for 51.”
ResultSelf-citationThe Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
Al-Samkari, H. T., & Connors, J. M. (2018) · Cancers · doi:10.3390/cancers10080271 · Cited by 41
“With the AMPLIFY-EXT [46] and EINSTEIN CHOICE [47] trials demonstrating benefit of reduced-dose anticoagulation with apixaban or rivaroxaban beyond 6 months in the general VTE population, with only modest additional bleeding risk, many providers will look to extrapolate this data to DOAC-treated cancer patients.”
MethodWang, X., Ma, Y., Xu, H., Li, M., Li, J., Tian, J., Wang, Q., Yan, P., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub3 · Cited by 52
Siniscalchi, C., Quintavalla, R., Rocci, A., Riera‐Mestre, A., Trujillo‐Santos, J., Suriñach, J. M., Jara‐Palomares, L., Bikdeli, B., Moustafa, F., & Monréal, M. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.07.028 · Cited by 37
Панченко, Е. П., Balahonova, T. V., Danilov, N. M., Komarov, A. L., Станиславовна, К. Е., Saidova, M. A., Shakhmatova, O. O., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-1-44-77 · Cited by 39
Frost, C. E., Cui, Y., Song, Y. J., Wang, J. J. J., Yu, Z., Schuster, A. E., & Barrett, Y. C. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s51981 · Cited by 38
“Apixaban is also being developed for the treatment of venous thromboembolism.(6,7) Variations in the pharmacokinetic and pharmacodynamic properties of anticoagulants such as heparin and warfarin, as well as resulting clotting times, were observed among different racial groups, including different Asian ethnicities.”
BackgroundAnticoagulantes orales directos: puesta al día
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.042 · Cited by 39
Anticoagulation at the extremes of body weight: choices and dosing
McCaughan, G. J. B., Favaloro, E. J., Pasalic, L., & Curnow, J. L. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1517040 · Cited by 36
Rivaroxaban and the EINSTEIN clinical trial programme
Cohen, A. T., & Bauersachs, R. M. (2019) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000800 · Cited by 43
Self-citationPrincipal Component Analysis on Recurrent Venous Thromboembolism
Martins, T. D., Annichino‐Bizzacchi, J. M., Romano, A. V. C., & Filho, R. M. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619895323 · Cited by 39
Jennings, I., Kitchen, D. P., Keeling, D. M., Fitzmaurice, D. A., & Heneghan, C. J. (2014) · British Journal of Haematology · doi:10.1111/bjh.13070 · Cited by 36
“…viable alternatives to warfarin (Connolly et al, 2009; Schulman et al, 2009, 2013; Bauersachs et al, 2010; Granger et al, 2011; Buller et al, 2012; Agnelli et al, 2013a,b; Giugliano et al, 2013; Hokusai-Investigators, 2013), and these drugs have received National Institute for Health and Care…”
BackgroundCaldeira, D., Canastro, M., Barra, M., Ferreira, A., Costa, J. N., Pinto, F. J., & Ferreira, J. J. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.0985 · Cited by 39
Mandernach, M. W., Beyth, R. J., & Rajasekhar, A. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s68010 · Cited by 40
“In the AMPLIFY-EXT study, Agnelli et al further evaluated the use of apixaban for extended prophylaxis following initial treatment for VTE.”
InfluentialTherapy for Cancer-Related Thromboembolism
Frère, C., Debourdeau, P., Hij, A., Cajfinger, F., N'Guessan, M., Panicot‐Dubois, L., Dubois, C., & Farge, D. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.04.005 · Cited by 37
Cohen, A. T., Imfeld, S., & Rider, T. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0119-7 · Cited by 40
“During studies of extended treatment of VTE, only dabigatran was compared with VKA treatment and was associated with significantly less major or clinically relevant non-major bleeding [20].”
BackgroundMethodResultInfluentialSelf-citationCohen, A. T., Imfeld, S., Markham, J., & Granziera, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.036 · Cited by 38
“5 mg dose) [29], rivaroxaban [30], and”
Self-citationBradbury, C. A., Fletcher, K., Sun, Y., Heneghan, C. J., Gardiner, C., Roalfe, A. K., Hardy, P., McCahon, D., Heritage, G., Shackleford, H., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16275 · Cited by 44
“…(Beccattini et al, 2012; Brighton et al, 2012) and four evaluated direct oral anticoagulants (DOACs) (Bauersachs et al, 2010; Romualdi et al, 2011; Agnelli et al, 2013; Schulman et al, 393 (40%, 393/993) pa ents fulfilled trial eligibility criteria 281 (72%, 281/393) commi ed to baseline research…”
Diagnosis and Management of Pulmonary Embolism
Trott, T., & Bowman, J. (2022) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2022.05.008 · Cited by 48
Chen, X., Wang, L., Li, H., Huang, W., Zhao, L., & Guo, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1049283 · Cited by 44
Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Bea, S., Iyer, G. S., Kim, D., Lin, K. J., Zhang, Y., Zakoul, H., Tesfaye, H., & Bykov, K. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1109 · Cited by 39
Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants
Wharin, C., & Tagalakis, V. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.11.001 · Cited by 36
“The authors concluded that additional information is needed to adequately assess the safety and efficacy of apixaban for treatment of cancer-associated VTE [29,30].”
BackgroundMethodLong-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE
Wells, P. S., Prins, M. H., Levitan, B. S., Beyer‐Westendorf, J., Brighton, T., Bounameaux, H., Cohen, A. T., Davidson, B. L., Prandoni, P., Raskob, G. E., et al. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.05.023 · Cited by 40
Self-citationDirect oral anticoagulants and venous thromboembolism
Franchini, M., & Mannucci, P. M. (2016) · European Respiratory Review · doi:10.1183/16000617.0025-2016 · Cited by 40
Breadth of complications of long-term oral anticoagulant care
Ageno, W., & Donadini, M. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.432 · Cited by 40
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Caterina, R. D., Ageno, W., Agnelli, G., Chan, N., Diener, H., Hylek, E. M., Raskob, G. E., Siegal, D. M., Verheugt, F. W. A., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675816 · Cited by 37
Self-citationVenous thromboembolism: A clinician update
Serhal, M., & Barnes, G. D. (2019) · Vascular Medicine · doi:10.1177/1358863x18821159 · Cited by 37
Pawar, A. M., Gagne, J. J., Gopalakrishnan, C., Iyer, G. S., Tesfaye, H., Brill, G. E., Chin, K., & Bykov, K. (2022) · JAMA · doi:10.1001/jama.2022.1920 · Cited by 34
Long-term clinical course of acute pulmonary embolism
den Exter, P. L., van der Hulle, T., Lankeit, M., Huisman, M. V., & Klok, F. A. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.06.003 · Cited by 42
“5 mg twice daily (“prophylactic dose”, 840 patients, 35% PE, 93% unprovoked VTE), apixaban 5 mg twice daily (“therapeutic dose”, 813 patients, 35% PE, 91% unprovoked VTE), or placebo for a duration of twelve months after initial anticoagulation therapy of six to twelve months [63].”
BackgroundTran, H. A., Merriman, E., Baker, R. I., Curnow, J. L., Young, L., Tan, C.-W., McRae, S. J., & Chunilal, S. D. (2025) · Internal Medicine Journal · doi:10.1111/imj.70103 · Cited by 34
Mai, V., Bertoletti, L., Cucherat, M., Mainbourg, S., Grangé, C., Provencher, S., & Lega, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214134 · Cited by 35
Extended Anticoagulation for VTE
Mai, V., Guay, C.-A., Perreault, L., Bonnet, S., Bertoletti, L., Lacasse, Y., Mainbourg, S., Lega, J., & Provencher, S. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.02.402 · Cited by 38
McBane, R. D., Loprinzi, C. L., Ashrani, A. A., Lenz, C. J., Houghton, D. E., Zemla, T., Le‐Rademacher, J. G., & Wysokiński, W. E. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13338 · Cited by 33
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation
Barnes, G. D., Kanthi, Y. M., & Froehlich, J. B. (2015) · Vascular Medicine · doi:10.1177/1358863x14566429 · Cited by 40
Oh, H. J., Ryu, K. H., Park, B. J., & Yoon, B. (2021) · Medicine · doi:10.1097/md.0000000000025216 · Cited by 34
Antithrombotic Drugs—Pharmacology and Perspectives
Li, T., Deshan, Y., & Yuan, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_4 · Cited by 36
Torramadé‐Moix, S., Palomo, M., Vera, M., Jerez, D., Moreno‐Castaño, A. B., Zafar, M. U., Rovira, J., Diekmann, F., García‐Pagán, J. C., Escolar, G., et al. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07010-z · Cited by 35
“Apixaban is an effective and safe DOAC agent with anti-FXa activity as demonstrated in multiple clinical trials [15, 26, 27].”
BackgroundUpdates in Cerebral Venous Thrombosis
Alimohammadi, A., Kim, D. J., & Field, T. S. (2022) · Current Cardiology Reports · doi:10.1007/s11886-021-01622-z · Cited by 37
Wu, C. M., Alotaibi, G., AlSaleh, K. A., & McMurtry, M. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.07.001 · Cited by 34
“Clinical trials have shown each of these agents to be at least as effective and safe as VKAs for the acute treatment of VTE and the secondary prevention of recurrent VTE [9–15].”
BackgroundPrandoni, P., Vedovetto, V., Ciammaichella, M. M., Bucherini, E., Corradini, S., Enea, I., Cosmi, B., Mumoli, N., Visonà, A., Barillari, G., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.04.002 · Cited by 36
Mukdad, M. A., Al‐Badriyeh, D., & Elewa, H. F. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619849103 · Cited by 34
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism
Giustozzi, M., Franco, L., Vedovati, M. C., Becattini, C., & Agnelli, G. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01878-x · Cited by 38
Self-citationAmin, A., Bruno, A. S., Trocio, J. N., Lin, J., & Lingohr-Smith, M. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1007210 · Cited by 37
Weitz, J. I., Jaffer, I., & Fredenburgh, J. C. (2017) · F1000Research · doi:10.12688/f1000research.11174.1 · Cited by 38
Self-citationDirect oral anticoagulants: An update
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.005 · Cited by 34
Riess, H. B., Ay, C., Bauersachs, R. M., Becattini, C., Beyer‐Westendorf, J., Cajfinger, F., Chau, I., Cohen, A. T., Khorana, A. A., Maraveyas, A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0473 · Cited by 33
Self-citationBouée, S., Emery, C., Samson, A., Gourmelen, J., Bailly, C., & Cotté, F.-E. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0078-0 · Cited by 38
“8 % of patients [13, 14, 29, 30].”
Role of the anticoagulant monitoring service in 2018: beyond warfarin
Clark, N. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.348 · Cited by 35
“The prophylactic doses were studied for extended secondary VTE prevention in a population for whom there was clinical equipoise regarding continued anticoagulant therapy for VTE management.(29,30) Prophylactic doses have efficacy similar to that of treatment doses, and a recent meta-analysis of the apixaban and rivaro…”
BackgroundBrenner, B., Arya, R., Beyer‐Westendorf, J., Douketis, J. D., Hull, R. D., Elalamy, I., Imberti, D., & Zhai, Z. (2019) · Thrombosis Journal · doi:10.1186/s12959-019-0214-8 · Cited by 34
Cornell, R. F., Goldhaber, S. Z., Engelhardt, B. G., Moslehi, J. J., Jagasia, M., Patton, D., Harrell, S. L., Hall, R., Wyatt, H., & Piazza, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00045 · Cited by 30
“of a pulmonary artery filling defect detected by contrastenhanced chest CT, an intraluminal filling defect detected by invasive pulmonary angiography, or confirmation of PE at autopsy (25).”
BackgroundShaya, S. A., Saldanha, L. J., Vaezzadeh, N., Zhou, J., Ni, R., & Gross, P. L. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13182 · Cited by 31
Loffredo, L., Violi, F., & Perri, L. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.086 · Cited by 31
Age‐adjusted D‐dimer cutoff for the diagnosis of pulmonary embolism: A cost‐effectiveness analysis
Blondon, M., Gal, G. L., Meyer, G., Righini, M., & Robert‐Ebadi, H. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14733 · Cited by 31
Rosovsky, R. P., Kline-Rogers, E., Lake, L., Minichiello, T., Piazza, G., Ragheb, B., Waldron, B., Witt, D. M., & Moll, S. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.01.010 · Cited by 29
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- McMaster University (CA)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139785591
- Cited by
- 1,366
- References
- 19
- Citations by year
- 2026: 70 · 2025: 80 · 2024: 64 · 2023: 68 · 2022: 90 · 2021: 98 · 2020: 101 · 2019: 114 · 2018: 103 · 2017: 89 · 2016: 109 · 2015: 133 · 2014: 141 · 2013: 102
- FWCI
- 81.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, venous thromboembolism, long-term anticoagulation, factor Xa inhibitors, recurrent venous thromboembolism, thromboprophylaxis, major bleeding, mortality, dose comparison, oral anticoagulants, clinical equipoise, post-thrombotic syndrome, pulmonary embolism, deep vein thrombosis
- MeSH terms
- Adult, Aged, Creatinine, Double-Blind Method, Female, Fibrinolytic Agents, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Recurrence, Treatment Outcome, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.